Some synthetic PPAR ligands have been widely used in the treatment of dyslipidemia (e.g., fibrates–PPARα activators) and diabetes mellitus (e.g., thiazolidinediones–PPARγ agonists) [30,31]. This evidence concerns the gene PPARG and diabetes mellitus.